The U.S. Food and Drug Administration has granted approval to Otsuka’s newly developed injectable therapy for patients diagnosed with primary immunoglobulin A nephropathy (IgAN), ...
ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...